Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Christine Birdwell, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Joseph D. Khoury, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-140212

Published: 2020

Journal Articles

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Christopher Peter Mill, PhD BA, Warren Fiskus, BSc,PhD, Dyana T. Saenz, PhD, Bernardo H Lara, Vrajesh Karkhanis, PhD, Taghi Manshouri, PhD, Isean Bhalla, Nancy Shao, James V Maher, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 538.

https://doi.org/10.1182/blood-2019-125142

Published: 2019

Journal Articles

Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells

Uri Rozovski, MD, David M. Harris, PhD, Ping Li, PhD, Zhiming Liu, BS, Taghi Manshouri, PhD, Ivo Veletic, MD, Preetesh Jain, MBBS,MDDM,PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A. Thompson, MBBS, Nitin Jain, MD, Srdan Verstovsek, MD PhD, William G. Wierda, MD PhD, Michael J Keating, MBBS, Zeev E. Estrov, MD

Blood (2019) 134 (Supplement_1): 3018.

https://doi.org/10.1182/blood-2019-124014

Published: 2019

Journal Articles

STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes

Taghi Manshouri, PhD, Ivo Veletic, MD, Ying Zhang, MD MS, Joseph E. Bove, IV, BS, Ping Li, PhD, David M. Harris, PhD, Zhiming Liu, BS, Evan N. Cohen, PhD, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD

Blood (2019) 134 (Supplement_1): 2961.

https://doi.org/10.1182/blood-2019-132054

Published: 2019

Journal Articles

Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL

Blood (2019) 134 (Supplement_1): 3024.

https://doi.org/10.1182/blood-2019-124183

Published: 2019

Journal Articles

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Warren Fiskus, BSc,PhD, Christopher Peter Mill, PhD BA, Vrajesh Karkhanis, PhD, Bernardo H Lara, Prithviraj Bose, MD, Lucia Masarova, Tapan M. Kadia, MD, Nancy Shao, Isean Bhalla, James V Maher, Joseph D. Khoury, MD, Sunil Sharma, MD, Taghi Manshouri, PhD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2019) 134 (Supplement_1): 1274.

https://doi.org/10.1182/blood-2019-130783

Published: 2019

Journal Articles

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Dyana T. Saenz, PhD, Warren Fiskus, BSc,PhD, Taghi Manshouri, PhD, David N Saenz, Raffaella Soldi, Baohua Sun, MD PhD, Christopher Peter Mill, PhD BA, Agnieszka J Nowak, Steven M. Kornblau, MD, Prithviraj Bose, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Lucia Masarova, MD, Steve Horrigan, Joseph David Khoury, MD, Sunil Sharma, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 177.

https://doi.org/10.1182/blood-2018-177

Published: 2018

Journal Articles

Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis

Taghi Manshouri, PhD, Ivo Veletic, MD, C. Cameron Yin, MD PhD, Lei Chen, MD, Joseph E. Bove, IV, Ying Zhang, MDMS, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD

Blood (2018) 132 (Supplement 1): 1793.

https://doi.org/10.1182/blood-2018-99-119064

Published: 2018

Journal Articles

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

Srdan Verstovsek, MD PhD, Robert P. Hasserjian, MD, Olga Pozdnyakova, MD PhD, Ivo Veletic, MD, Ruben A. Mesa, MD, Lynda Foltz, MD FRCPC, John Mascarenhas, MD, Ellen K. Ritchie, MD, Jeanne Palmer, MD, Richard T. Silver, MD, Marina Kremyanskaya, MD PhD, Bernt van den Blink, MD PhD, Renu Gupta, MD, Taghi Manshouri, PhD, C. Cameron Yin, MD PhD, Zeev E. Estrov, MD, Jason R. Gotlib, MDMS

Blood (2018) 132 (Supplement 1): 686.

https://doi.org/10.1182/blood-2018-99-115362

Published: 2018

Journal Articles

PD-1-Mediated T Cell Exhaustion Is Prevalent Among Patients with MPN-Associated Myelofibrosis Independent of JAK1/2 Inhibition

Ivo Veletic, MD, Taghi Manshouri, PhD, Graciela M. Nogueras González, MPH, Sanja Prijic, PhD, Joseph E. Bove, IV, Ying Zhang, MD MS, Srdan Verstovsek, MD PhD, Zeev E. Estrov, MD

Blood (2018) 132 (Supplement 1): 5487.

https://doi.org/10.1182/blood-2018-99-119428

Published: 2018

Journal Articles

Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis

Ivo Veletic, MD, Taghi Manshouri, PhD, Sanja Prijic, PhD, C. Cameron Yin, MD PhD, Joseph E Bove, IV, BS, Ying Zhang, MD MS, Srdan Verstovsek, MD PhD, Zeev Estrov, MD

Blood (2016) 128 (22): 4280.

https://doi.org/10.1182/blood.V128.22.4280.4280

Published: 2016

Journal Articles

Loss of Normal T-Cell Subset Distribution in Myelofibrosis Is Recovered By the Immunomodulatory Effects of JAK1/2 Inhibition

Sanja Prijic, PhD, Taghi Manshouri, PhD, Ivo Veletic, MD, Kate J Newberry, PhD, Ying Zhang, MD MS, Joseph E Bove, IV, BS, Zeev Estrov, MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 3138.

https://doi.org/10.1182/blood.V128.22.3138.3138

Published: 2016

Journal Articles

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Dyana T Saenz, PhD, Warren Fiskus, PhD, Kanak Raina, PhD, Taghi Manshouri, PhD, Kevin Coleman, PhD, Jim Winkler, PhD, Yimin Qian, PhD, Andrew Crew, PhD, Angela Shen, MD, Christopher P Mill, PhD, Baohua Sun, MD PhD, Srdan Verstovsek, MD PhD, Craig Crews, PhD, Kapil N. Bhalla, MD

Blood (2016) 128 (22): 747.

https://doi.org/10.1182/blood.V128.22.747.747

Published: 2016

Journal Articles

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Dyana T Saenz, Warren Fiskus, PhD, Taghi Manshouri, PhD, Baohua Sun, MD PhD, Stephanie Krieger, Simrit Parmar, MD, Srdan Verstovsek, MD PhD, Kapil N. Bhalla, MD

Blood (2015) 126 (23): 1269.

https://doi.org/10.1182/blood.V126.23.1269.1269

Published: 2015

Journal Articles

Amplification of hnRNP K Drives c-Myc-Dependent Malignancies and Represent a Novel Therapeutic Opportunity for Hematologic Malignancies

Miguel Gallardo, PhD, Xiaorui Zhang, BS, Mark McArthur, Taghi Manshouri, PhD, Sean M. Post, PhD

Blood (2015) 126 (23): 468.

https://doi.org/10.1182/blood.V126.23.468.468

Published: 2015

Journal Articles

Ruxolitinib Treatment Induces a Transition of Classical to Non-Classical Monocytes in Patients with Myelofibrosis

Sanja Prijic, PhD, Taghi Manshouri, PhD, Ying Zhang, MD MS, Ivo Veletic, MD, Xiaorui Zhang, BS, Joseph E Bove, IV, BS, Zeev Estrov, MD, Srdan Verstovsek, MD

Blood (2015) 126 (23): 2838.

https://doi.org/10.1182/blood.V126.23.2838.2838

Published: 2015

Journal Articles

hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML

Miguel Gallardo, PhD, Hun Ju Lee, MD, Xiaorui Zhang, BS, Carlos E. Bueso-Ramos, MD, Laura Pageon, Mark McArthur, Asha Multani, Aziz Nazha, MD, Taghi Manshouri, PhD, Jan Parker-Thornburg, Peter Hu, Yuan Qi, Xiaoping Su, PhD, Inmaculada Rapado, Alfonso Quintás-Cardama, Steven M. Kornblau, MD, Joaquin Martinez-López, MDPhD, Sean M. Post, PhD

Blood (2015) 126 (23): 439.

https://doi.org/10.1182/blood.V126.23.439.439

Published: 2015

Journal Articles

Do Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients with Primary Myelofibrosis?

Lucia Masarova, MD, Naval Daver, MD, Naveen Pemmaraju, MD, Prithviraj Bose, MD, Sherry Pierce, BSN, BA, Taghi Manshouri, PhD, Jorge E. Cortes, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD

Blood (2015) 126 (23): 4069.

https://doi.org/10.1182/blood.V126.23.4069.4069

Published: 2015

Journal Articles

BONE Marrow Stromal CELL Paracrine Factors from PMF Patients, but NOT Healthy Donors, Protect JAK2 V617F CELLS from Ruxotinib-Induced Apoptosis

Taghi Manshouri, PhD, Zeev Estrov, MD, Liza Knez, BSC, Ying Zhang, Ksenija Bozinovic, Vilma Dembitz, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 1872.

https://doi.org/10.1182/blood.V124.21.1872.1872

Published: 2014

Journal Articles

Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

Neha Bhagwat, Priya Koppikar, Outi Kilpivaara, Taghi Manshouri, PhD, Mazhar Adli, Ann Mullally, MD, Omar Abdel-Wahab, MD, Laura Leung, Abby Weinstein, Sachie Marubayashi, Aviva Goel, Mithat Gonen, Zeev Estrov, Benjamin L. Ebert, MD, D.Phil, Gabriela Chiosis, PhD, Bradley Bernstein, Srdan Verstovsek, MD, PhD, Ross L Levine, MD

Blood (2011) 118 (21): 122.

https://doi.org/10.1182/blood.V118.21.122.122

Published: 2011

NARROW

Pre-Clinical Efficacy of Co-Targeting GFI1/KDM1A and BRD4 or JAK1/2 Against AML and Post-MPN Secondary AML Blast Progenitor Cells

Mechanistic Basis and Efficacy of Targeting β-Catenin-TCF7L2-JMJD6-MYC Axis to Overcome Resistance to BET Inhibitors

Constitutively Activated STAT3 Induces the Expression of Gli1 in Chronic Lymphocytic Leukemia Cells

STAT3-Induced Gli1 Promotes the Differentiation and Maturation of Myelofibrosis Fibrocytes

Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLL

Pre-Clinical Efficacy of Co-Treatment with KDM1A (LSD1) Inhibitor and Ruxolitinib or BET Inhibitor Against Post-MPN-sAML Blast Progenitor Cells

Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis

Bone Marrow Fibrocytes Overexpress Gli1 Oncogenic Transcription Factor in Primary Myelofibrosis

PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study

PD-1-Mediated T Cell Exhaustion Is Prevalent Among Patients with MPN-Associated Myelofibrosis Independent of JAK1/2 Inhibition

Multiplex Quantitative Imaging Analysis of Bone-Remodeling Cells in Patients with Myelofibrosis

Loss of Normal T-Cell Subset Distribution in Myelofibrosis Is Recovered By the Immunomodulatory Effects of JAK1/2 Inhibition

Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells

Superior Activity of BET Protein Bromodomain Antagonist-Based Combination with JAK Kinase, PIM Kinase or Heat Shock Protein 90 Inhibitor Against Post-MPN-MF sAML Cells

Amplification of hnRNP K Drives c-Myc-Dependent Malignancies and Represent a Novel Therapeutic Opportunity for Hematologic Malignancies

Ruxolitinib Treatment Induces a Transition of Classical to Non-Classical Monocytes in Patients with Myelofibrosis

hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML

Do Patients with Post-Essential Thrombocythemia and Post-Polycythemia Vera Differ from Patients with Primary Myelofibrosis?

BONE Marrow Stromal CELL Paracrine Factors from PMF Patients, but NOT Healthy Donors, Protect JAK2 V617F CELLS from Ruxotinib-Induced Apoptosis

Heterodimeric JAK-STAT Activation As a Mechanism of Persistence to JAK2 Inhibitor Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only